Clinical Trial Detail

NCT ID NCT03580694
Title Study of REGN4659 in Combination With Cemiplimab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Regeneron Pharmaceuticals
Indications

lung non-small cell carcinoma

Therapies

Cemiplimab + REGN4659

Cemiplimab

Age Groups: senior adult

Additional content available in CKB BOOST